Induced regulatory T cells in inhibitory microenvironments created by cancer

Expert Opinion on Biological Therapy

Volumn 14, Issue 10, 2014, Pages 1411-1425

  Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer; Immune suppression; Inducible regulatory T cell; Inhibitory pathways; Regulatory T cell directed therapy; Tumor microenvironment

Indexed keywords

ADENOSINE; CANCER VACCINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; DENILEUKIN DIFTITOX; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; NEUROPILIN; PROSTAGLANDIN E2; SEMAPHORIN; SUNITINIB; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; EFFECTOR CELL; FLOW CYTOMETRY; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOPHENOTYPING; INFLAMMATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T CELL DEPLETION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; TUMOR ESCAPE;

HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84907055119     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.927432     Document Type: Review

References (125)

1. Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 2012;22:327-34
2. Whiteside TL, Schuler P, Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 2012;12:1383-97
3. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FOXP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012;18:3022-9
4. Duhen T, Duhen R, Lanzavecchia A, et al. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 2012;119:4430-40
5. Abbas AK, Benoist C, Bluestone JA, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 2013;14:307-8
6. Andersen MH, Sø rensen RB, Brimnes MK, et al. Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest 2009;119(8):2245-56
7. Addey C, White M, Dou L, et al. Functional plasticity of antigen-specific regulatory T cells in context of tumor. J Immunol 2011;186:4557-64
8. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74
9. Long SA, Buckner JH. CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game. J Immunol 2011;187:2061-6
10. Adeegb e DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front Immunol 2013;4:190
11. Mougiakakos D, Choudhury A, Lladser A, et al. Regulatory T cells in cancer. Adv Cancer Res 2010;107:57-117
12. Schuler PJ, Macatangay BJ, Saze Z, et al. CD4+CD73+ T cells are associated with lower T cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression. AIDS 2013;27:1545-55
13. Canavan JB, Afzali B, Scotta C, et al. A rapid diagnostic test for human regulatory T cell function to enable regulatory T cell therapy. Blood 2012;119:e57-66
14. Ruitenberg JJ, Boyce C, Hingorani R, et al. Rapid assessment of in vitro expanded human regulatory T cell function. J Immunol Methods 2011;372:95-106
15. Piersma SJ, van der Hulst JM, Kwappenberg KM, et al. Influenza matrix 1-specific human CD4+FOXP3+ and FOXP3(-) regulatory T cells can be detected long after vi ral clearance. Eur J Immunol 2010;40:3064-74
16. Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associated with longer patient survival. Nat Med 2012;18:1254-61
17. Vukmanovic-Stejic M, Zhang Y, Cook JE, et al. Human CD4+ CD25hi FOXP3+ regulatory T cells are derived by rapid turnover of memory population s in vivo. J Clin Invest 2006;116:2423-33
18. Liu W,Putnam AL,Xu-Yu Z,et al. CD127 expression inversely correlates with FOXP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203: 1701-11.
19. Mandapathil M, Szczepanski M, Harasymczuk M, et al. CD26 expression and adenos ine deaminase activity in regulatory T cells (Treg) and CD4(+) T effector cells in patients with head and neck squamous cell carcinoma. Oncoimmunology 2012;1:659-69
20. Strauss L, Bergmann C, Whiteside T L. Functional and phenotypic characteristics of CD4+CD25highFOXP3+ Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer 2007;121:2473-83
21. Fazilleau N, Bachelez H, Gouge on ML, Viguier M. Cutting edge: size and diversity of CD4+CD25high FOXP3+ regulatory T cell repertoire in humans: evidence for similarities and partial overlapping with CD4+CD25-T cells. J Immunol 2007;179:3412-16
22. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor FOXP3. Science 2003;299:1057-61
23. Beyer M, Thabet Y, Muller RU, et al. Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol 2011;12:898-907
24. McInnes N, Sadlon TJ, Brown CY, et al. FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells. Oncogene 2012;31:1045-54
25. Schuler PJ, Schilling B, Harasymczuk M, et al. Phenotypic and f unctional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T cell subsets in cancer patients. Eur J Immunol 2012;42:1876- 85
26. Bergmann C, Strauss L, Wang Y, et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008;14:3706-15
27. Elkord E, Al-Ramadi BK. Helios expression in FoxP3(+) T regulatory cells. Expert Opin Biol Ther 2012;12:1423-5
28. Raffin C, Pignon P, Celse C, et al. Human memory Helios-FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that exp ress Aiolos and respond to IL-1b by downregulating their suppressor functions. J Immunol 2013;191:4619-27
29. Himmel ME, MacDonald KG, Garcia RV, et al. Helios+ and Helioscells coexist within the natural FOXP3+ T regulatory cell subset in humans. J Immunol 2013;190:2001-8
30. Strauss L, Bergmann C, Szczepanski MJ, et al. Expression of ICOS on human melanoma-infiltrating CD4 +CD25highFox p3+ T regulatory cells: implications and impact on tumormediated immune suppression. J Immunol 2008;180(5):2967-80
31. Zaunders JJ, Munier ML, Seddiki N, et al. High levels of human antigens pecific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol 2009;183:2827-36
32. Xiao X, Gong W, Demirci G, et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol 2012;188:892-901
33. Milpied P, Renand A, Bruneau J, et al. Neuropilin-1 is not a marker of human Foxp3+ Treg. Eur J Immunol 2009;39(6):1466-71
34. Chaudhary B, Khaled YS, Ammori BJ, Elkord E. Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother 2014;63:81-99
35. Ondondo B, Jones E, Godkin A, Gallimore A. Home sweet home: the tumor microenvironment as a haven for regulatory T cells. Front Immunol 2013;4:197
36. Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition o n CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008;111:453-62
37. Mandapathil M, Hilldorfer B, Szczepanski MJ, et al. Generation and accumulation of immunosu ppressive adenosine by human CD4 +CD25highFOXP3+ regulatory T cells. J Biol Chem 2010;285:7176-86
38. Schuler PJ, Saze Z, Hong CS, et al. Human CD4(+) CD39(+) regulatory T cells produce adenosin e upon co-expression of surface CD73 or contact with CD73(+) exosomes or CD73(+) cells. Clin Exp Immunol 2014, doi: 10.1111/cei.12354. [Epub ahead of print]
39. Stockis J,Colau D,Coulie PG,Lucas S. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol. 2009; 39:3315-22.
40. Tran DQ, Andersson J, Wang R, et al. GARP (LRRC32) is essential f or the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci USA 2009;106:13445-50
41. Sun J, Tang DN, Fu T, Sharma P. Identification of h uman regulatory T cells in the setting of T cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide. Cancer Discov 2012;2:122-30
42. Strauss L, Bergmann C, Whiteside TL. Human circulating CD4 +CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol 2009;182:1469-80
43. Czystowska M, Strauss L, Bergmann C, et al. Reciprocal granzyme/perforinmediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J Mol Med (Berl) 2010;88:577-88
44. Vignali DA, Col lison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008;8:523-32
45. Cheng G, Yu A, Malek TR. T cell tolerance and the multi-functional role of IL-2R signaling in T regulatory cells. Immunol Rev 2011;241:63-76
46. Cheng G, Yu A, Dee MJ, Malek TR. IL-2R signaling is essential for functional maturation of regulatory T cells during thymic development. J Immunol 2013;190:1567-75
47. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates bet ween human regulatory and activated T cells. J Exp Med 2006;203:1693-700
48. Lopez CB, Rao TD, Feiner H, et al. Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumo r-infiltrating lymphocytes. Cell Immunol 1998;190:141-55
49. Yu A, Zhu L, Altman NH, Malek TR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 2009;30:204-17
50. Strauss L, Bergmann C, Gooding W, et al. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:6301-11
51. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72
52. Pandiyan P, Zheng L, Ishihara S, et al. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosi s of effector CD4+ T cells. Nat Immunol 2007;8:1353-62
53. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365:2055-66
54. Saadoun D, Rosenzwaig M, Joly F, et al. Regulatory T cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365:2067-77
55. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009;30(6):899-911
56. Rech AJ, Mick R, Martin S, et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med 2012;4:134ra62
57. Schuler PJ, Harasymczuk M, Schilling B, et al. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin Cancer Res 2013;19:6585-96
58. Oida T, Weiner HL. Overexpression of TFG-b 1 gene induces cell surface localized glucose-regulated protein 78-associated latency-associated peptide/TGF-b. J Immunol 2010;185:3529-35
59. Zhang L, Bertucci AM, Ramsey-Goldman R, et al. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunologic al remission of lupus. J Immunol 2009;183:6346-58
60. Li MO,Wan YY,Sanjabi S,et al, Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99-146.
61. Rubtsov YP, Rudensky AY. TGFbeta signaling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 2007;7:443-53
62. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000;12:171-81
63. Mempel TR, Pittet MJ, Khazaie K, et al. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 2006;25:129-41
64. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25-naïve T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:1875-86
65. Nakamura K, Kitani A, Fuss I, et al. TGF-beta 1 plays an important role in the mechanisms of CD4+CD24+ regulatory T cell activity in both humans and mice. J Immunol 2004;172:834-42
66. Andersson J, Tran DQ, Pesu M, et al. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 2008;205:1975-81
67. White RA, Malkoski SP, Wang XJ. TGF-beta signaling in head and neck squamous cell carcinoma. Oncogene 2010;29:5437-46
68. Sitkovksy MV. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 2008;30:102-8
69. Regateiro FS, Howie D, Nolan KF, et al. Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-beta. Eur J Immunol 2011;41:2955-65
70. Hasko G , Linden J, Cronstein Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008;7:759-70
71. Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013;13:842-57
72. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010;30:5346-58
73. Zhou X, Zhi X, Zhou P, et al. Effects of ecto-5'-nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol Rep 2007;17:1341-6
74. Whiteside TL, Jackson EK. Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease. Front Immunol 2013;4:212
75. Su Y, Huang X, Raskovalova T, et al. Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression. Cancer Immunol Immunother 2008;57:1611-23
76. Su Y,Jackson EK,Gorelik E, Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol I mmunother. 2011;60:111-22.
77. Whiteside TL. Disarming suppressor cells to improve immunotherapy. Cancer Immunol Immunother 2012;61:283-8
78. Muller-Haegele S, Mull er L, Whiteside TL. Immunoregulatory activity of adenosine and its role in human cancer progression. Exp Rev Clin Immunol. In press 2014
79. Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expre ssion of ectonucleotidase CD39 by FoxP3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-32
80. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-65
81. Ohta A, Kini R, Ohta A, et al. The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol 2012;3:190
82. Mandapathil M, Szczepanski MJ, Szajnik M, et al. A denosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 2010;285:27571-80
83. Kinsey GR, Huang L, Jaworska K, et al. Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol 2012;23(9):1528-37
84. Delgoffe GM, Woo SR, Turnis ME, et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 2013;501:252-6
85. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004;4:665-74
86. Jin D, Fan J, Wang L, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 2010;70:2245-55
87. Bastid J, Cottalorda-Regairaz A, Alberici G, et al. ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 2013;32:1743-51
88. Le DT, Jaffee EM. Regulatory T-ce ll modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 2012;72:3439-44
89. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009;1174:99-106
90. Baur AS, Lutz MB, Schierer S, et al. Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg. Blood 2013;122:2185-94
91. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82
92. El kord E, Alcantar-Orozco EM, Dovedi SJ. T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther 2010;10:1573-86
93. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6
94. Tarhini AA, Igbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 2010;3:15-25
95. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73:3591-603
96. Camisaschi C, Casati C, Rini F, et al. LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 2010;184:6545-51
97. Yan J,Zhang Y,Zhang JP,et al, Tim-3 expression defines regulatory T cells in human tumors. PLoS One. 2013;8:e58006.
98. Gao X, Zhu Y, Li G, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 2012;7:e30676
99. Jie HB, Gildener-Leapman N, Li J, et al. I ntratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013;109:2629-35
100. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
101. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33
102. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
103. Curran MA, Montalvo W, Yahita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells with B16 melanoma tumors. Proc Natl Acad Sci USA 2010 ;107:4275-80
104. Whiteside TL. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 2010;10:1019-35
105. Wang D, DuBois RN. The role of antiinflammatory drugs in colorectal cancer. Annu Rev Med 2013;64:131-44
106. Bergmann C, Strauss L, Zeidler R, et al. Expansion of h uman T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007;67:8865-73
107. Mandapathil M, Whiteside TL. Targeting hum an inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E2 cooperation. Expert Opin Biol Ther 2011;11:1203-14
108. Mandapathil M, Szczepanski MJ, Szajnik M, et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 2009;15:6348-57
109. Stagg J, Divisekera U, McLaughlin N, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 2010;107:1547-52
110. Wang L, Zhou X, Zhou T, et al. Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 2008;134:365-72
111. Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med 2013;19:355-67
112. Allard B, Turcotte M, Stagg J. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol 2012;2012:485156
113. Sim GC, Martin-Orozco N, Jin L, et al. IL-2 therapy promotes suppressive ICOS + Treg expansion in melanoma patients. J Clin Invest 2014;124:99-110
114. E ggermont AM. Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin Cancer Res 2009;15:6745-7
115. Kuss I, Hathaway B, Ferris RL, et al. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;10:3755-62
116. Rech AJ, Mick R, Kaplan DE, et al. Homeostasis of peripheral FoxP3(+) CD4(+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol Immunother 2010;59:599-607
117. Schaue D, Xie MW, Rati kan JA, McBride WH. Regulatory T cells in radiotherapeutic responses. Front Oncol 2012;2:90
118. Colombo MP, Piconese S. Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007;7:880-7
119. Moltedo B,Hemmers S,Rudensky AY,Regulatory T cell ablation causes acute T cell lymphopenia. PLoS One. 2014;9:e86762.
120. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014;27C:1-7
121. Burocchi A, Colombo MP, Piconese S. Convergences and divergences of thymusand peripherally derived regulatory T cells in cancer. Front Immunol 2013;4:247
122. Schmitt EG, Williams CB. Generation and function of induced regulatory T cells. Front Immunol 2013;4:152
123. Mandapathil M, Visus C, Fin n OJ, et al. Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells. Oncoimmunology 2013;2:e25514
124. Houot R, Goldstein MJ, Kohrt HE, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009;114(16):3431-8
125. Polansky JK, Shreiber L, Thelemann C, et al. Methylation matters: bi nding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells. J Mol Med (Berl) 2010;88:1029-40